ClinicalTrials.gg
CompletedNCT03691623Updated May 3, 2022Results posted

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

A Phase 2 interventional study of EDP-938 Dose 1 and EDP-938 Dose 2 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
2nd of 10
179 · median 81
Started
2018
with 2 others
Phase 2
4 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 4 in phase 2, and was the 2nd registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.

03

Conditions studied

  • RSV Infection

Keywords

  • challenge study
  • RSV
  • antiviral
  • RSV-A Memphis 37b
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject
  • Age 18 to 55 years, inclusive
  • In good health with no history of major medical conditions
  • A total body weight ≥ 50 kg and (BMI) ≥ 18 kg/m\^2 and ≤ 30kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing females
  • Acute or chronic medical illness
  • Abnormal lung function
  • Positive for (HIV), active hepatitis A, B or C test
  • Nose or nasopharynx abnormalities
  • Receipt of any drug within 3 months prior to the planned date of viral challenge/first dose of study drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    EDP-938 Arm A

    Subjects will take EDP-938 Dose 1 oral suspension for 5 days

    Drug: EDP-938 Dose 1

  • Experimental
    EDP-938 Arm B

    Subjects will take EDP-938 Dose 2 oral suspension for 5 days

    Drug: EDP-938 Dose 2

  • Placebo comparator
    Placebo Arm C

    Subjects will take matching placebo oral suspension for 5 days

    Drug: Placebo

  • Experimental
    EDP-938 Arm D

    Subjects will take EDP-938 Dose 3 oral suspension for 5 days

    Drug: EDP-938 Dose 3

  • Experimental
    EDP-938 Arm E

    Subjects will take EDP-938 Dose 4 oral suspension for 5 days

    Drug: EDP-938 Dose 4

  • Placebo comparator
    Placebo Arm F

    Subjects will take matching placebo oral suspension for 5 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load

    Measured in nasal washes by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in participants inoculated with respiratory syncytial virus-A (RSV-A) Memphis 37b.

    Time frame: Twice daily on Day 2 through Day 11 and once on Day 12

Secondary outcomes

  1. Area Under the Curve (AUC) of Total Symptom Score

    Total symptom scores (from the 10-item Diary Card) were used to calculate the AUC. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). Data presented is hours x score.

    Time frame: Three times daily on Day 0 to Day 11, once on Day 12

  2. Peak Total Symptom Score

    Peak total symptom score was defined as the highest total symptom score between first dose of study drug and Day 12. Values presented are a sum of individual symptom scores, with a potential range of 0 (best) to 30 (worst). Total symptom scores at the time of the first dose of study drug can be before or after dosing. Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness

    Time frame: Day 2 to Day 12

  3. Total Symptom Score

    Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities. Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness

    Time frame: Day 2 to Day 9

  4. Time to Peak Total Symptom Score

    Time to peak total symptom score was defined as the time in days to the highest total symptom score between first dose of study drug and Day 12. Total symptom scores at the time of the first dose of study drug can be before or after dosing.

    Time frame: Day 2 to Day 12

  5. Time to Resolution From Peak Total Symptom Score

    Time to resolution from peak total symptom score was defined as the time in days from the highest total symptom score (between first dose of study drug and Day 12) until the start of the first 24-hour symptom-free period (after the highest total symptom score). Total symptom scores at the time of the first dose of study drug can be before or after dosing.

    Time frame: Day 2 to Day 12

  6. Total Weight of Nasal Mucus Produced

    Measured via weighed paper tissues and reported as a mean total across all study days.

    Time frame: Day 2 to Day 12

  7. Peak Viral Load

    Peak viral load was defined as the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.

    Time frame: Day 2 to Day 12

  8. Time to Peak Viral Load

    Time to peak viral load was defined as the time to the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.

    Time frame: Day 2 to Day 12

  9. Time to Resolution From Peak Viral Load

    Time to resolution from peak viral load was defined as the time from peak until first confirmed undetectable assessment between first dose of study drug and Day 12. Measured by by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).

    Time frame: Day 2 to Day 12

  10. Time to Cessation of Virus Detection

    Time to cessation of virus detection was measured by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).

    Time frame: Day 2 to Day 12

  11. Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant physical examinations, vital signs, clinical laboratory tests (including biochemistry, hematology, coagulation \[if required\], cardiac enzymes and urine analysis), 12-lead electrocardiograms (ECGs) and spirometry results were recorded as adverse events.

    Time frame: Day 2 to Day 28

  12. Maximum Plasma Concentration (Cmax) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  13. Time to Maximum Plasma Concentration (Tmax) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  14. Terminal Phase Half-Life (t1/2) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  15. Apparent Systemic Clearance at Steady State (CLss/F) of EDP-938

    Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  16. Terminal Phase Rate Constant Calculated by Linear Regression of the Terminal Loglinear Portion of the Concentration vs. Time Curve (λz) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  17. Volume of Distribution at Steady State (Vss/F) of EDP-938

    Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  18. Plasma Concentration at 12 Hours (C12) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2 and Day 7; 12 hours post-dose

  19. Plasma Concentration at 24 Hours (C24) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2 and Day 7; 24 hours post-dose

  20. Area Under the Concentration Time Curve Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  21. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of EDP-938 and Its Metabolites

    The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

    Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose

  22. Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC

    The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable viral load AUC i.e. a low PK AUC and a high viral load AUC indicated a correlation.

    Time frame: Day 2 to Day 18

  23. Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC

    The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable TSS AUC, i.e. a low PK AUC and a high TSS AUC indicated a correlation.

    Time frame: Day 2 to Day 18

07

Results

Posted May 3, 2022

Participant flow

A total of 179 participants enrolled in the trial at one site in the United Kingdom from October 2018 to October 2019.

Participant flow — Overall Study
MilestonePart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Started393838212121
Inoculated with challenge virus393838212121
Received treatment383838212121
Completed393838212121
Not completed000000

Outcome measures

PrimaryArea Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load

Measured in nasal washes by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in participants inoculated with respiratory syncytial virus-A (RSV-A) Memphis 37b.

Time frame:
Twice daily on Day 2 through Day 11 and once on Day 12
Reported as:
Geometric mean · hours*log10 copies/milliliter (mL)
Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load
hours*log10 copies/milliliter (mL)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load134.70 ± 85.1113.51 ± 99.9624.30 ± 51.780.61 ± 112.1160.81 ± 63.3808.28 ± 37.1
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -588.08 · 95% CI -719.8 to -456.35
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -564.63 · 95% CI -689.23 to -440.02
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -716.08 · 95% CI -879.92 to -552.24
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -736.23 · 95% CI -916.36 to -556.11
SecondaryArea Under the Curve (AUC) of Total Symptom Score

Total symptom scores (from the 10-item Diary Card) were used to calculate the AUC. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). Data presented is hours x score.

Time frame:
Three times daily on Day 0 to Day 11, once on Day 12
Reported as:
Geometric mean · hours*score
Area Under the Curve (AUC) of Total Symptom Score
hours*scorePart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Area Under the Curve (AUC) of Total Symptom Score61.18 ± 347.837.36 ± 1640.1252.49 ± 243.926.70 ± 730.227.81 ± 436.8232.53 ± 530.9
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -355.91 · 95% CI -506.12 to -205.69
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -326.64 · 95% CI -469.68 to -183.6
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = = 0.001 · Ls mean difference: -313.98 · 95% CI -494.27 to -133.69
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = = 0.003 · Ls mean difference: -312.73 · 95% CI -508.05 to -117.4
SecondaryPeak Total Symptom Score

Peak total symptom score was defined as the highest total symptom score between first dose of study drug and Day 12. Values presented are a sum of individual symptom scores, with a potential range of 0 (best) to 30 (worst). Total symptom scores at the time of the first dose of study drug can be before or after dosing. Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness

Time frame:
Day 2 to Day 12
Reported as:
Geometric mean · Scores on a scale
Peak Total Symptom Score
Scores on a scalePart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Peak Total Symptom Score2.3 ± 53.91.9 ± 89.84.9 ± 77.91.6 ± 68.51.8 ± 55.64.2 ± 85.8
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -3.7 · 95% CI -5.3 to -2
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -3.9 · 95% CI -5.5 to -2.4
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = = 0.002 · Ls mean difference: -3 · 95% CI -4.9 to -1.2
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = = 0.006 · Ls mean difference: -2.9 · 95% CI -4.9 to -0.9
SecondaryTotal Symptom Score

Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities. Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness

Time frame:
Day 2 to Day 9
Reported as:
Geometric mean · Scores on a scale
Total Symptom Score
Scores on a scalePart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Relative Day 2 Assessment 10.9 ± 97.50.8 ± 155.41.9 ± 117.00.5 ± 140.80.3 ± 222.53.0 ± 66.6
Relative Day 2 Assessment 20.8 ± 94.00.7 ± 160.32.4 ± 110.30.4 ± 185.20.5 ± 179.82.9 ± 82.5
Relative Day 2 Assessment 30.5 ± 117.00.6 ± 184.42.7 ± 94.90.3 ± 196.20.2 ± 331.72.6 ± 94.3
Relative Day 3 Assessment 10.4 ± 137.30.7 ± 148.52.6 ± 99.10.4 ± 166.90.2 ± 254.22.2 ± 103.0
Relative Day 3 Assessment 20.4 ± 144.30.6 ± 175.22.7 ± 90.50.3 ± 207.00.3 ± 237.12.3 ± 101.0
Relative Day 3 Assessment 30.3 ± 190.90.6 ± 167.72.5 ± 103.70.2 ± 332.60.3 ± 276.42.2 ± 95.3
Relative Day 4 Assessment 10.3 ± 177.10.5 ± 154.92.3 ± 103.80.2 ± 343.90.2 ± 254.21.9 ± 92.6
Relative Day 4 Assessment 20.3 ± 186.50.6 ± 163.11.8 ± 115.30.1 ± 387.30.1 ± 331.71.7 ± 85.0
Relative Day 4 Assessment 30.3 ± 263.00.4 ± 163.51.8 ± 103.10.2 ± 280.30.1 ± 331.71.8 ± 88.3
Relative Day 5 Assessment 10.2 ± 228.20.5 ± 158.91.6 ± 108.30.2 ± 244.90.2 ± 254.21.6 ± 87.9
Relative Day 5 Assessment 20.3 ± 191.30.4 ± 177.11.4 ± 109.20.2 ± 314.00.2 ± 254.21.4 ± 112.8
Relative Day 5 Assessment 30.1 ± 364.80.4 ± 162.01.3 ± 115.90.1 ± 280.30.1 ± 331.71.4 ± 89.6
Relative Day 6 Assessment 10.2 ± 300.90.4 ± 186.91.2 ± 106.00.2 ± 314.00.2 ± 237.11.5 ± 83.3
Relative Day 6 Assessment 20.2 ± 288.70.4 ± 186.91.0 ± 112.80.1 ± 387.30.3 ± 185.41.2 ± 102.4
Relative Day 6 Assessment 30.2 ± 280.90.3 ± 184.61.0 ± 100.50.1 ± 387.30.1 ± 210.81.1 ± 116.5
Relative Day 7 Assessment 10.2 ± 225.10.2 ± 205.30.7 ± 124.90.1 ± 387.30.1 ± 316.20.8 ± 126.1
Relative Day 7 Assessment 20.2 ± 196.20.2 ± 162.00.7 ± 115.70.1 ± 346.40.1 ± 300.00.9 ± 153.5
Relative Day 7 Assessment 30.2 ± 291.00.2 ± 185.80.9 ± 89.90.1 ± 331.70.0 ± NA0.7 ± 179.2
Relative Day 8 Assessment 10.1 ± 291.00.2 ± 199.90.9 ± 94.90.1 ± 331.70.0 ± NA0.5 ± 153.7
Relative Day 8 Assessment 20.1 ± 374.20.1 ± 244.10.9 ± 99.40.2 ± 264.60.0 ± NA0.2 ± 170.8
Relative Day 8 Assessment 30.0 ± NA0.4 ± 149.10.6 ± 129.10.0 ± NA—0.2 ± 200.0
Relative Day 9 Assessment 10.0 ± NA0.0 ± NA0.4 ± 140.50.0 ± NA—0.2 ± 200.0
Relative Day 9 Assessment 20.0 ± NA0.0 ± NA0.5 ± 91.30.0 ± NA—0.4 ± 141.4
SecondaryTime to Peak Total Symptom Score

Time to peak total symptom score was defined as the time in days to the highest total symptom score between first dose of study drug and Day 12. Total symptom scores at the time of the first dose of study drug can be before or after dosing.

Time frame:
Day 2 to Day 12
Reported as:
Geometric mean · Days
Time to Peak Total Symptom Score
DaysPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Time to Peak Total Symptom Score1.18 ± 137.81.76 ± 110.02.15 ± 71.41.45 ± 131.91.09 ± 136.41.94 ± 80.5
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = = 0.199 · Ls mean difference: -0.82 · 95% CI -2.09 to 0.44
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = = 0.714 · Ls mean difference: 0.22 · 95% CI -0.98 to 1.43
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = = 0.844 · Ls mean difference: -0.19 · 95% CI -2.15 to 1.77
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = = 0.21 · Ls mean difference: -1.34 · 95% CI -3.46 to 0.79
SecondaryTime to Resolution From Peak Total Symptom Score

Time to resolution from peak total symptom score was defined as the time in days from the highest total symptom score (between first dose of study drug and Day 12) until the start of the first 24-hour symptom-free period (after the highest total symptom score). Total symptom scores at the time of the first dose of study drug can be before or after dosing.

Time frame:
Day 2 to Day 12
Reported as:
Geometric mean · Days
Time to Resolution From Peak Total Symptom Score
DaysPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Time to Resolution From Peak Total Symptom Score2.49 ± 70.12.83 ± 77.53.30 ± 61.72.19 ± 70.01.38 ± 116.55.17 ± 383
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = = 0.145 · Ls mean difference: -1.01 · 95% CI -2.37 to 0.36
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = = 0.352 · Ls mean difference: -0.65 · 95% CI -2.03 to 0.73
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = = 0.002 · Ls mean difference: -2.85 · 95% CI -4.55 to -1.15
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -3.4 · 95% CI -5.19 to -1.61
SecondaryTotal Weight of Nasal Mucus Produced

Measured via weighed paper tissues and reported as a mean total across all study days.

Time frame:
Day 2 to Day 12
Reported as:
Mean · Grams
Total Weight of Nasal Mucus Produced
GramsPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Total Weight of Nasal Mucus Produced12.965 ± 13.03147.428 ± 11.132433.416 ± 37.80722.983 ± 4.42264.716 ± 6.001522.391 ± 20.6005
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -24.081 · 95% CI -36.554 to -11.607
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -25.954 · 95% CI -37.695 to -14.213
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -18.13 · 95% CI -27.176 to -9.083
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -19.329 · 95% CI -29.106 to -9.552
SecondaryPeak Viral Load

Peak viral load was defined as the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.

Time frame:
Day 2 to Day 12
Reported as:
Mean · log10 copies/milliliter (mL)
Peak Viral Load
log10 copies/milliliter (mL)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Peak Viral Load4.3552 ± 1.563344.3111 ± 1.769746.4727 ± 1.606593.9718 ± 1.788734.7727 ± 1.350147.0973 ± 1.24388
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2.1292 · 95% CI -2.8491 to -1.4093
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2.1129 · 95% CI -2.7938 to -1.4319
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -3.2191 · 95% CI -4.1915 to -2.2467
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2.7831 · 95% CI -3.8522 to -1.714
SecondaryTime to Peak Viral Load

Time to peak viral load was defined as the time to the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.

Time frame:
Day 2 to Day 12
Reported as:
Geometric mean · Days
Time to Peak Viral Load
DaysPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Time to Peak Viral Load0.74 ± 75.60.80 ± 130.22.59 ± 48.50.88 ± 181.30.79 ± 64.03.43 ± 33.7
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2.01 · 95% CI -2.67 to -1.35
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -1.78 · 95% CI -2.4 to -1.16
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = = 0.009 · Ls mean difference: -1.98 · 95% CI -3.43 to -0.54
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = = 0.004 · Ls mean difference: -2.41 · 95% CI -4 to -0.82
SecondaryTime to Resolution From Peak Viral Load

Time to resolution from peak viral load was defined as the time from peak until first confirmed undetectable assessment between first dose of study drug and Day 12. Measured by by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).

Time frame:
Day 2 to Day 12
Reported as:
Geometric mean · Days
Time to Resolution From Peak Viral Load
DaysPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Time to Resolution From Peak Viral Load2.03 ± 72.12.02 ± 79.74.03 ± 47.51.67 ± 77.11.63 ± 43.73.58 ± 45.6
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2.1 · 95% CI -3.04 to -1.17
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2 · 95% CI -2.89 to -1.11
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -1.97 · 95% CI -3.06 to -0.89
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · ANCOVA · p = < 0.001 · Ls mean difference: -2.46 · 95% CI -3.64 to -1.29
SecondaryTime to Cessation of Virus Detection

Time to cessation of virus detection was measured by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).

Time frame:
Day 2 to Day 12
Reported as:
Median · Days
Time to Cessation of Virus Detection
DaysPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Time to Cessation of Virus Detection3.5 (2.0 to 4.5)3.2 (1.5 to 4.5)8.5 (6.5 to NA)2.7 (1.5 to 4.0)2.5 (1.5 to 3.5)8.5 (7.0 to 9.0)
Statistical analysis
  • Part 1: EDP-938 600 mg vs Part 1: Placebo · Log Rank · p = < 0.001
  • Part 1: EDP-938 500 mg Then 300 mg vs Part 1: Placebo · Log Rank · p = < 0.001
  • Part 2: EDP-938 600 mg Then 300 mg vs Part 2: Placebo · Log Rank · p = = 0.001
  • Part 2: EDP-938 400 mg Then 200 mg vs Part 2: Placebo · Log Rank · p = < 0.001
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant physical examinations, vital signs, clinical laboratory tests (including biochemistry, hematology, coagulation \[if required\], cardiac enzymes and urine analysis), 12-lead electrocardiograms (ECGs) and spirometry results were recorded as adverse events.

Time frame:
Day 2 to Day 28
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs)20212181011
SecondaryMaximum Plasma Concentration (Cmax) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of EDP-938 and Its Metabolites
nanograms per milliliter (ng/mL)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-938 First Dose1370 ± 49.71151 ± 46.91237.91 ± 33.2800.73 ± 44.9
EDP-938 Last Dose1740 ± 52.81480 ± 33.41010 ± 15.9901 ± 27.9
EP-024636 First Dose256 ± 39.3215 ± 41.3264 ± 42.0177 ± 48.2
EP-024636 Last Dose361 ± 34.8342 ± 27.8230 ± 23.0232 ± 32.0
EP-024594 First Dose96.3 ± 48.176.8 ± 54.8102 ± 61.172.3 ± 49.1
EP-024594 Last Dose203 ± 32.6240 ± 30.1130 ± 44.1168 ± 32.9
EP-024595 First Dose150 ± 63.2102 ± 79.6167 ± 81.1100 ± 72.1
EP-024595 Last Dose717 ± 45.61000 ± 49.1499 ± 89.0692 ± 50.5
SecondaryTime to Maximum Plasma Concentration (Tmax) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) of EDP-938 and Its Metabolites
HoursPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-938 First Dose4.56 (2.0 to 10.0)5.00 (1.0 to 12.0)5.80 (1.9 to 10.2)6.07 (2.0 to 10.2)
EDP-938 Last Dose4.52 (1.9 to 17.0)4.10 (0.0 to 10.1)4.98 (1.0 to 15.9)4.04 (0.0 to 10.0)
EP-024636 First Dose5.91 (2.9 to 23.5)5.97 (2.0 to 12.0)7.97 (3.1 to 11.9)6.99 (2.0 to 11.8)
EP-024636 Last Dose5.00 (2.8 to 15.0)4.88 (0.5 to 8.0)6.00 (3.0 to 17.0)4.04 (0.0 to 8.3)
EP-024594 First Dose10.07 (4.1 to 24.1)10.23 (4.0 to 12.0)11.83 (6.2 to 23.8)10.14 (4.9 to 11.9)
EP-024594 Last Dose8.07 (4.0 to 20.1)4.98 (0.0 to 12.0)8.00 (0.5 to 17.2)5.03 (0.0 to 8.3)
EP-024595 First Dose23.72 (8.0 to 24.1)11.85 (8.0 to 12.2)23.75 (11.8 to 24.0)11.83 (5.8 to 12.0)
EP-024595 Last Dose10.90 (3.0 to 22.0)5.07 (0.4 to 12.0)11.88 (2.8 to 22.3)4.04 (0.0 to 9.9)
SecondaryTerminal Phase Half-Life (t1/2) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · Hours
Terminal Phase Half-Life (t1/2) of EDP-938 and Its Metabolites
HoursPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-93814.5 ± 25.413.8 ± 27.414.5 ± 31.313.7 ± 23.5
EP-02463614.5 ± 21.513.4 ± 21.114.4 ± 29.813.5 ± 21.2
EP-02459417.8 ± 18.216.2 ± 18.517.5 ± 25.115.4 ± 17.0
EP-02459528.5 ± 38.225.5 ± 25.122.7 ± 15.623.0 ± 19.4
SecondaryApparent Systemic Clearance at Steady State (CLss/F) of EDP-938
Time frame:
Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · litres per hour
Apparent Systemic Clearance at Steady State (CLss/F) of EDP-938
litres per hourPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
Apparent Systemic Clearance at Steady State (CLss/F) of EDP-93826.9 ± 44.824.1 ± 28.421.3 ± 17.625.0 ± 23.9
SecondaryTerminal Phase Rate Constant Calculated by Linear Regression of the Terminal Loglinear Portion of the Concentration vs. Time Curve (λz) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · 1/hour
Terminal Phase Rate Constant Calculated by Linear Regression of the Terminal Loglinear Portion of the Concentration vs. Time Curve (λz) of EDP-938 and Its Metabolites
1/hourPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-9380.05 ± 1.20.05 ± 1.60.05 ± 1.50.05 ± 1.2
EP-0246360.05 ± 1.10.05 ± 1.20.05 ± 1.30.05 ± 1.1
EP-0245940.04 ± 0.70.04 ± 0.80.04 ± 1.00.05 ± 0.8
EP-0245950.03 ± 1.30.03 ± 0.90.03 ± 0.50.03 ± 0.6
SecondaryVolume of Distribution at Steady State (Vss/F) of EDP-938
Time frame:
Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · litre(s)
Volume of Distribution at Steady State (Vss/F) of EDP-938
litre(s)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
Volume of Distribution at Steady State (Vss/F) of EDP-938560 ± 42.8476 ± 23.1442 ± 24.1491 ± 28.8
SecondaryPlasma Concentration at 12 Hours (C12) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2 and Day 7; 12 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Concentration at 12 Hours (C12) of EDP-938 and Its Metabolites
nanograms per milliliter (ng/mL)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-938 First Dose—679.35 ± 34.5—565.60 ± 39.5
EDP-938 Last Dose—822 ± 35.2—525 ± 30.0
EP-024636 First Dose—168 ± 32.1—149 ± 41.0
EP-024636 Last Dose—228 ± 27.8—153 ± 28.9
EP-024594 First Dose—75.3 ± 54.4—68.8 ± 50.8
EP-024594 Last Dose—188 ± 27.4—133 ± 31.7
EP-024595 First Dose—100 ± 79.6—99.3 ± 75.4
EP-024595 Last Dose—705 ± 39.1—515 ± 40.2
SecondaryPlasma Concentration at 24 Hours (C24) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2 and Day 7; 24 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Concentration at 24 Hours (C24) of EDP-938 and Its Metabolites
nanograms per milliliter (ng/mL)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-938 First Dose404 ± 46.9—453 ± 31.6—
EDP-938 Last Dose491 ± 56.4—287 ± 74.0—
EP-024636 First Dose121 ± 43.5—136 ± 30.5—
EP-024636 Last Dose148 ± 44.4—88.3 ± 64.8—
EP-024594 First Dose78.8 ± 43.7—87.8 ± 56.0—
EP-024594 Last Dose127 ± 29.3—74.5 ± 72.4—
EP-024595 First Dose142 ± 57.5—163 ± 79.4—
EP-024595 Last Dose461 ± 41.6—287 ± 93.8—
SecondaryArea Under the Concentration Time Curve Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of EDP-938 and Its Metabolites
ng*hr/mLPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-938 First Dose16730 ± 47.07540 ± 45.816420 ± 24.05970 ± 40.5
EDP-938 Last Dose32000 ± 52.927300 ± 40.820500 ± 32.117800 ± 29.0
EP-024636 First Dose3800 ± 42.91490 ± 49.34080 ± 36.21300 ± 45.9
EP-024636 Last Dose8680 ± 42.97690 ± 32.85550 ± 24.15180 ± 28.8
EP-024594 First Dose1610 ± 55.3512 ± 73.11740 ± 64.2487 ± 51.5
EP-024594 Last Dose6880 ± 31.77160 ± 27.54320 ± 37.34990 ± 31.6
EP-024595 First Dose2510 ± 72.1540 ± 95.62420 ± 83.1541 ± 67.1
EP-024595 Last Dose29600 ± 40.536900 ± 38.419700 ± 77.125800 ± 46.6
SecondaryArea Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of EDP-938 and Its Metabolites

The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.

Time frame:
Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of EDP-938 and Its Metabolites
ng*hr/mLPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
EDP-93822300 ± 46.512500 ± 29.714100 ± 18.58010 ± 24.9
EP-0246365770 ± 36.13270 ± 25.23640 ± 24.52210 ± 30.8
EP-0245943830 ± 30.62470 ± 26.12410 ± 45.41710 ± 33.8
EP-02459512100 ± 41.98950 ± 36.78350 ± 82.06210 ± 44.3
SecondaryNumber of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC

The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable viral load AUC i.e. a low PK AUC and a high viral load AUC indicated a correlation.

Time frame:
Day 2 to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC
ParticipantsPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC0000
SecondaryNumber of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC

The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable TSS AUC, i.e. a low PK AUC and a high TSS AUC indicated a correlation.

Time frame:
Day 2 to Day 18
Reported as:
Count of participants · Participants
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC
ParticipantsPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mg
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC0000

Adverse events

Collected over All cause mortality was monitored from enrollment until end of study (Day 28) for the safety analysis population which included all participants who received challenge virus, regardless of whether they received study drug or not. Treatment-emergent serious and other adverse events (AEs) were monitored from Day 2 to Day 28 and only included participants in the safety analysis population who received study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: EDP-938 600 mg0/39 (0%)0/38 (0%)20/38 (52.6%)
Part 1: EDP-938 500 mg Then 300 mg0/38 (0%)0/38 (0%)21/38 (55.3%)
Part 1: Placebo0/38 (0%)0/38 (0%)21/38 (55.3%)
Part 2: EDP-938 600 mg Then 300 mg0/21 (0%)0/21 (0%)8/21 (38.1%)
Part 2: EDP-938 400 mg Then 200 mg0/21 (0%)0/21 (0%)10/21 (47.6%)
Part 2: Placebo0/21 (0%)0/21 (0%)11/21 (52.4%)
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPart 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: Placebo
NauseaGastrointestinal disorders1/381/383/381/213/210/21
Upper respiratory tract infectionInfections and infestations2/382/384/381/212/211/21
DizzinessNervous system disorders4/380/381/380/212/211/21
HeadacheNervous system disorders4/381/383/380/211/212/21
Viral upper respiratory tract infectionInfections and infestations1/380/381/380/212/210/21
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/380/380/380/212/210/21
DiarrhoeaGastrointestinal disorders3/383/380/381/211/210/21
Ear painEar and labyrinth disorders0/381/382/380/211/210/21
Abdominal painGastrointestinal disorders0/382/381/380/210/211/21
DyspepsiaGastrointestinal disorders1/382/380/380/210/210/21

Baseline characteristics

In Part 1, one participant in the Safety Analysis Set did not receive study treatment and is not included in this baseline analysis population.

Age, Categorical
Age, Categorical(Participants)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: PlaceboTotal
<=18 years0000000
Between 18 and 65 years383838212121177
>=65 years0000000
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: PlaceboTotal
Female1318131011974
Male252025111012103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: EDP-938 600 mgPart 1: EDP-938 500 mg Then 300 mgPart 1: PlaceboPart 2: EDP-938 600 mg Then 300 mgPart 2: EDP-938 400 mg Then 200 mgPart 2: PlaceboTotal
American Indian or Alaska Native0000000
Asian1121106
Native Hawaiian or Other Pacific Islander0000000
Black or African American0120104
White333231181719150
More than one race0000000
Unknown or Not Reported44322217
08

Study locations

1 site
  • hVIVO Services Limited (hVIVO)
    London, United Kingdom
09

References and documents

Publications

  • Ahmad A, Eze K, Noulin N, Horvathova V, Murray B, Baillet M, Grey L, Mori J, Adda N. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge. N Engl J Med. 2022 Feb 17;386(7):655-666. doi: 10.1056/NEJMoa2108903. PubMed 35172056 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2019, 11 months.

Results were first posted in May 2022, 2 years 7 months after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 11 months is close to that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2018
First posted
Oct 2, 2018
StartActual
Oct 15, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Oct 18, 2019
Results first posted
May 3, 2022
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03691623
Collaborators
hVIVO Services Limited
Responsible party
Sponsor
First posted
Oct 2, 2018
Start date
Oct 15, 2018
Primary completion
Sep 30, 2019
Completion
Oct 18, 2019
Results posted
May 3, 2022
Last update
May 3, 2022

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion